Stocks · News reference
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.